# NCT01844505 (NCT01844505)

> Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01844505
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Unresectable or Metastatic Melanoma
- Interventions: Nivolumab; Ipilimumab; Placebo for Nivolumab; Placebo for Ipilimumab
- Enrollment: 945
- Primary outcome: Progression Free Survival (PFS)
- Primary outcome: Overall Survival (OS)
- Primary outcome: Rate of Overall Survival
- Primary outcome: Rate of Progression-Free Survival

## Commentary we found

- Podcasts: 46
- YouTube: 30
- X threads: 22

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct01844505

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01844505", "email": "<work email>"}; the inbox owner confirms by the emailed link.